On Friday, Shares of Petróleo Brasileiro S.A. - Petrobras (NYSE:PBR), gained 1.21% to $8.38, after the Brazilian state-run oil company received interest from potential buyers for a stake in its gas pipeline, according to Bloomberg.
Potential suitors counting Mitsui & Co. (MITSY) and Marubeni (MARUY) are preparing bids for the 49% stake in its Gaspetro pipeline, which Petrobras hopes to sell by July 17.
Petrobras has formerly declared plans to divest up to $15.1 billion in assets by the starting of next year.
Petróleo Brasileiro S.A. Petrobras operates as an integrated energy company in Brazil and internationally. Its Exploration and Production segment engages in the exploration, development, and production of crude oil, natural gas liquids, and natural gas; and sale of crude oil and oil products produced at natural gas processing plants in domestic and foreign markets.
Shares of CSX Corp. (NYSE:CSX), inclined 0.72% to $32.13, during its last trading session.
The Board of Directors of CSX Corporation, approved a $0.18 per share quarterly dividend on the company’s common stock. The dividend is payable on September 15, 2015, to shareholders of record at the close of business on August 31, 2015.
CSX Corporation, together with its auxiliaries, provides rail-based transportation services in the United States and Canada. It offers traditional rail services, and transports intermodal containers and trailers. The company transports crushed stone, sand and gravel, metal, phosphate, fertilizer, food, consumer, agricultural, automotive, paper, and chemical products.
Finally, Dynavax Technologies Corporation (NASDAQ:DVAX), ended its last trade with 6.32% gain, and closed at $28.11, hitting its highest level.
Dynavax Technologies Corporation, declared that the independent Data and Safety Monitoring Board (DSMB) charged with periodically reviewing safety data from HBV-23, the ongoing Phase 3 clinical study of HEPLISAV-B, Dynavax’s investigational adult hepatitis B vaccine, has accomplished its third pre-specified review and has recommended that the study continue unchanged.
The third DSMB review comprised of safety data for all enrolled subjects collected through the data cut-off in June. As of the cut-off, all ongoing subjects who had received the second immunization (which was the last active dose for HEPLISAV-B subjects) had reached at least 8 months of the requisite one year follow-up after the second immunization. The DSMB reviewed unblinded tables and listings presenting key safety data. Based on this review, the DSMB recommended ongoing HBV-23 with no change to the study.
Over 2,200 subjects have accomplished their final study visit and all study visits for HBV-23 are predictable to be accomplished by October 2015. Top line results are predictable to be released by early 2016.
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the United States. It development programs focus on the areas of vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
